Katherine Talcott, MD:

Hi, there. I'm Katherine Talcott, and I just had the opportunity to finish presenting at ARVO. While I was here, I had the opportunity to present on the phase two VERONA study, looking at EYP-1901 in patients with diabetic macular edema. TKIs have generated a ton of interest as sort of small molecules that may be able to decrease the injection burden for some of our patients with neovascular AMD and diabetic macular edema. And in the VERONA study, we looked at patients who had EYP-1901 compared to aflibercept two milligrams to be able to see if there was a decrease in the amount of supplementation that these patients needed from aflibercept to two milligrams. And we saw that in both of the doses of EYP-1901 that were used. So these patients had a longer time before they needed supplementation with aflibercept two milligrams.

One of the interesting things I was also seeing is that these patients, even after the first dose of EYP-1901, had a significant improvement in vision as well as a significant improvement in their anatomy as well. So this really supports the use of EYP-1901 as a six-month drug that's going to be further investigated in two phase three studies, COMO and CAPRI, that are actively enrolling. So I had a great time presenting at ARVO and thanks for listening.